

Berberine behind the thriller of marked symptomatic bradycardia

Margherita Cannillo, Simone Frea, Cristina Fornengo, Elisabetta Toso, Giancarlo Mercurio, Stefania Battista, Fiorenzo Gaita

Margherita Cannillo, Simone Frea, Cristina Fornengo, Elisabetta Toso, Fiorenzo Gaita, Division of Cardiology, Cardiovascular Department, AOU S. Giovanni Battista di Torino and University of Torino, 10100 Torino, Italy

Giancarlo Mercurio, Stefania Battista, Emergency Department, AOU S. Giovanni Battista di Torino and University of Torino, 10100 Torino, Italy

Author contributions: Cannillo M and Frea S designed the report and wrote the paper; Fornengo C, Frea S, Toso E, Mercurio G and Battista S were attending doctors for the patients; Cannillo M and Toso E performed ergometric stress test and ECG Holter; Toso E and Gaita F approved the final version to be published.

Correspondence to: Margherita Cannillo, MD, Division of Cardiology, Cardiovascular Department, AOU S. Giovanni Battista di Torino and University of Torino, Corso Bramante 88, 10100 Torino, Italy. margheritacannillo@gmail.com

Telephone: +39-11-6335571 Fax: +39-11-6335572
Received: April 23, 2013 Revised: June 7, 2013

Accepted: June 18, 2013

Published online: July 26, 2013

Abstract

Berberine is used in traditional Chinese medicine for the treatment of congestive heart failure, hypertension, diabetes, and dyslipidaemia and has a good safety profile. We report a case of a 53-year-old sportsman referred to our hospital for the onset of fatigue and dyspnoea upon exertion after he started berberine to treat hypercholesterolaemia. An electrocardiogram showed sinus bradycardia (45 bpm), first-degree atrioventricular block, and competitive junctional rhythm. An ergometric stress test showed slightly reduced chronotropic competence and the presence of runs of competitive junctional rhythm, atrial tachycardia, and sinus pauses in the recovery. After 10 d of wash-out from berberine, the patient experienced a complete resolution of symptoms, and an ergometric stress test showed good chronotropic competence. An electrocardiogram Holter

showed a latent hypervagotonic state. This is the first case report that shows that berberine could present certain side effects in hypervagotonic people, even in the absence of a situation that could cause drug accumulation. Therefore, berberine's use should be carefully weighed in hypervagotonic people due to the drug's bradycardic and antiarrhythmic properties, which could become proarrhythmic, exposing patients to potential health risks.

© 2013 Baishideng. All rights reserved.

Key words: Berberine; Bradyarrhythmia; Side effect; Hypervagotonia; Hypercholesterolaemia; Electrocardiogram

Core tip: Berberine is widely used in traditional Chinese medicine for the treatment of congestive heart failure, hypertension, diabetes, and dyslipidaemia. We report a case of marked symptomatic sinus bradycardia with competitive junctional rhythm caused by berberine, showing that berberine, due to its antiarrhythmic properties, can cause the onset of bradyarrhythmia. In this case report, we focus on the possible side effects of so-called natural medicine based on holistic, home, and herbal remedies, which is considered to be safe only because the treatment is natural. However, under certain conditions, natural medicine can lead to potential health risks in patients.

Cannillo M, Frea S, Fornengo C, Toso E, Mercurio G, Battista S, Gaita F. Berberine behind the thriller of marked symptomatic bradycardia. *World J Cardiol* 2013; 5(7): 261-264 Available from: URL: <http://www.wjgnet.com/1949-8462/full/v5/i7/261.htm> DOI: <http://dx.doi.org/10.4330/wjc.v5.i7.261>

INTRODUCTION

Berberine is an alkaloid from *Hydrastis canadensis* L., the




Figure 1 Competitive junctional rhythm.

Chinese herb Huang Lian, and many other plants. Berberine is widely used in traditional Chinese medicine for the treatment of congestive heart failure^[1-3], hypertension^[3], diabetes, and dyslipidaemia^[4-5]. Berberine has multiple cardiovascular effects, including negative chronotropic, antiarrhythmic and vasodilatory properties^[1,2] and an anti-inflammatory effect^[6]. Several cardiovascular effects of berberine are attributed to the blockade of K⁺ channels [delayed rectifier and K(ATP)], the stimulation of Na⁺-Ca²⁺ exchangers^[2,7], and the activation of cardiac M2 muscarinic cholinergic receptors^[8].

Berberine has been tested in acute coronary syndrome patients following percutaneous coronary intervention (PCI)^[6], in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy^[3], in menopausal women^[9], in elderly hypercholesterolaemic patients^[10], and in patients with metabolic syndrome^[11], offering various therapeutic strategies without evidence of side effects.

CASE REPORT

We report a brief case that shows that berberine could cause side effects under specific conditions.

A 53-year-old man was referred to the emergency room of our hospital after the onset of fatigue and dyspnoea upon exertion, with evidence of bradycardia. He was overweight and hyperlipidaemic and used to swim three times per week. His medical history was unremarkable, except that he had started berberine 6 d before to treat hypercholesterolaemia. Upon physical examination, the patient presented a normal blood pressure and oxygen saturation but an irregular heart rate of 50 bpm. He did not present signs of heart failure, and cardiac, pulmonary, and vascular examinations were normal. The electrocardiogram (ECG) showed sinus bradycardia with a heart rate of 45 bpm, first-degree atrioventricular block (PR interval of 280 ms), and a competitive junctional rhythm at 55 bpm (Figure 1). Both blood analysis and echocardiography did not show any justification for the marked bradycardia. An overdose of berberine was ruled out because the patient consumed the correct daily dose. Because berberine excretion is hepatobiliary^[12], the presence of any predisposing factor for reduced excretion,




Figure 2 Junctional beats, premature supraventricular beats, sometimes aberrant starting brief runs of atrial tachycardia.

such as hepatic or biliary disease, was examined and ruled out.

Given the bradycardic and antiarrhythmic properties of berberine, we decided to discontinue the drug, and based on the presence of dyspnoea upon exertion, an ergometric stress test was performed to evaluate chronotropic competence. A 24-h wash-out from berberine was sufficient before the test, as berberine's half-life is less than 30 min^[12]. The ergometric stress test showed slightly reduced chronotropic competence, with an increase in the heart rate from 45 bpm to 127 bpm, equivalent to 76% of the maximal prediction. The test also showed a reduction in the atrioventricular conduction delay, with a PR that reached 180 ms for a heart rate of 127 bpm. The patient presented a good functional class (the test was stopped at the second minute of the step second Bruce protocol, METs 13.5). The recovery was characterised by the presence of runs of competitive junctional rhythm; premature supraventricular beats that were occasionally aberrant, sporadically starting brief runs of atrial tachycardia (Figure 2); and a sinus pause with an RR of a maximum of 1.7 s (Figure 3A). Most likely, the patient's symptoms were not closely related to bradycardia at rest but rather to the loss of AV synchronisation during the junctional rhythm and to the reduction in chronotropic competence during stress.

Over the following days, the patient experienced a complete resolution of symptoms and performed normal life activities and his usual sport activity (swimming) without experiencing dyspnoea or fatigue. After 10 d of wash-out from berberine, he underwent a new ergometric stress test and an ECG Holter. The ergometric stress test was normal. The ECG at rest was characterised by the presence of sinus bradycardia with a heart rate of 43 bpm and first-degree atrioventricular block (PR at rest of 280 ms), as presented several days before. However, the test presented better chronotropic competence. The test was maximal (86% of the predicted heart rate), despite the patient having reached the same workload as in the first test. The presence of first-degree atrioventricular block was consistent with a PR interval normalised at a high rate.

During the ECG-Holter monitoring, we observed a




Figure 3 Sinus pause. A: With an RR of max 1.7 s; B: With an RR 2.4 s.

sight typical of a hypervagotonic state: bradycardial sinus rhythm with normal variation of the heart rate with a circadian cycle and physical activity (FC maximum 104, average 56, minimum 40 bpm); several nocturnal runs of sinus bradycardia at 30 bpm; and several, especially nocturnal sinus pauses, with an RR interval of 2.4 s (Figure 3B).

The patient continued to be asymptomatic and to practice his normal life and sport activities and treated his dyslipidaemia with diet.

DISCUSSION

This is the first case report that shows that berberine could present certain side effects in hypervagotonic people, even in the absence of a situation that could cause drug accumulation. Indeed, berberine has been found to have a good safety profile^[2,3,5,6,9-11] in patients with pathological conditions characterised by a hyperadrenergic state, such as acute coronary syndrome^[13], heart failure^[14,15], diabetes^[16], hypertension^[17], and menopause^[18]. In a murine model, it has been proven that berberine reduces plasma adrenaline and noradrenaline levels^[19]. We do not know whether the bradycardic and antiarrhythmic properties of berberine are vagally mediated by the activation of muscarinic receptors, as shown by Salehi *et al.*^[8], or are not vagally mediated, as reported by Shaffer^[20]. However, it is possible that in hypervagotonic people with marked sinus bradycardia, berberine's bradycardic effect can induce the onset of competitive junctional rhythm, causing a loss of atrioventricular synchronisation, and can reduce chronotropic competence with the onset of symptoms upon exertion. Therefore, berberine's use should be carefully weighed in hypervagotonic people due to the drug's bradycardic and antiarrhythmic proper-

ties, which could become proarrhythmic, exposing patients to potential health risks.

REFERENCES

- 1 **Lau CW**, Yao XQ, Chen ZY, Ko WH, Huang Y. Cardiovascular actions of berberine. *Cardiovasc Drug Rev* 2001; **19**: 234-244 [PMID: 11607041 DOI: 10.1111/j.1527-3466.2001.tb00068.x]
- 2 **Marin-Neto JA**, Maciel BC, Secches AL, Gallo Júnior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. *Clin Cardiol* 1988; **11**: 253-260 [PMID: 3365876 DOI: 10.1002/clc.4960110411]
- 3 **Zeng XH**, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2003; **92**: 173-176 [PMID: 12860219 DOI: 10.1016/S0002-9149(03)00533-2]
- 4 **Zhao HL**, Sui Y, Qiao CF, Yip KY, Leung RK, Tsui SK, Lee HM, Wong HK, Zhu X, Siu JJ, He L, Guan J, Liu LZ, Xu HX, Tong PC, Chan JC. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. *Diabetes* 2012; **61**: 933-943 [PMID: 22396199 DOI: 10.2337/db11-1164]
- 5 **Trimarco B**, Benvenuti C, Rozza F, Cimmino CS, Giudice R, Crispo S. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. *Med J Nutrition Metab* 2011; **4**: 133-139 [PMID: 21909461 DOI: 10.1007/s12349-010-0043-6]
- 6 **Meng S**, Wang LS, Huang ZQ, Zhou Q, Sun YG, Cao JT, Li YG, Wang CQ. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. *Clin Exp Pharmacol Physiol* 2012; **39**: 406-411 [PMID: 22220931 DOI: 10.1111/j.1440-1681.2012.05670.x]
- 7 **Li BX**, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. *Acta Pharmacol Sin* 2001; **22**: 125-131 [PMID: 11741516]
- 8 **Salehi S**, Filtz TM. Berberine possesses muscarinic agonist-like properties in cultured rodent cardiomyocytes. *Pharmacol Res* 2011; **63**: 335-340 [PMID: 21168503 DOI: 10.1016/j.phrs.2010.12.004]
- 9 **Cianci A**, Cicero AF, Colacurci N, Matarazzo MG, De Leo V. Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. *Gynecol Endocrinol* 2012; **28**: 699-702 [PMID: 22313171 DOI: 10.3109/09513590.2011.652250]
- 10 **Marazzi G**, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. *Adv Ther* 2011; **28**: 1105-1113 [PMID: 22113535 DOI: 10.1007/s12325-011-0082-5]
- 11 **Affuso F**, Mercurio V, Ruvolo A, Pirozzi C, Micillo F, Carlomagno G, Grieco F, Fazio S. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. *World J Cardiol* 2012; **4**: 77-83 [PMID: 22451856 DOI: 10.4330/wjc.v4.i3.77]
- 12 **Tsai PL**, Tsai TH. Hepatobiliary excretion of berberine. *Drug Metab Dispos* 2004; **32**: 405-412 [PMID: 15039293 DOI: 10.1124/dmd.32.4.405]
- 13 **Bonow RO**, Mann DL, Zipes DP, Libby P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume. 9th Edition. Tianjin: Tianjin Science and Technology Translation Publishing Ltd, 2013
- 14 **Esler M**, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. *Am J Cardiol* 1997; **80**: 7L-14L [PMID: 9412538 DOI: 10.1016/S0002-9149(97)00844-8]
- 15 **Grassi G**, Seravalle G, Quarti-Trevano F, Dell'oro R. Sympathetic activation in congestive heart failure: evidence, conse-

- quences and therapeutic implications. *Curr Vasc Pharmacol* 2009; **7**: 137-145 [PMID: 19355996 DOI: 10.2174/157016109787455699]
- 16 **Jacob G**, Costa F, Biaggioni I. Spectrum of autonomic cardiovascular neuropathy in diabetes. *Diabetes Care* 2003; **26**: 2174-2180 [PMID: 12832331 DOI: 10.2337/diacare.26.7.2174]
- 17 **Grassi G**. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. *Hypertension* 2009; **54**: 690-697 [PMID: 19720958 DOI: 10.1161/HYPERTENSIONAHA.108.119883]
- 18 **Hogarth AJ**, Graham LN, Corrigan JH, Deuchars J, Mary DA, Greenwood JP. Sympathetic nerve hyperactivity and its effect in postmenopausal women. *J Hypertens* 2011; **29**: 2167-2175 [PMID: 21941208]
- 19 **Hong Y**, Hui SS, Chan BT, Hou J. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. *Life Sci* 2003; **72**: 2499-2507 [PMID: 12650858 DOI: 10.1016/S0024-3205(03)00144-9]
- 20 **Shaffer JE**. Inotropic and chronotropic activity of berberine on isolated guinea pig atria. *J Cardiovasc Pharmacol* 1985; **7**: 307-315 [PMID: 2581085 DOI: 10.1097/00005344-198503000-00016]

P- Reviewers De Ponti R, Alzand BSN **S- Editor** Wen LL
L- Editor A **E- Editor** Lu YJ

